These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 33277443)

  • 1. A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
    Kawakami M; Mustachio LM; Chen Y; Chen Z; Liu X; Wei CH; Roszik J; Kittai AS; Danilov AV; Zhang X; Fang B; Wang J; Heymach JV; Tyutyunyk-Massey L; Freemantle SJ; Kurie JM; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2021 Mar; 20(3):477-489. PubMed ID: 33277443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer.
    Kawakami M; Mustachio LM; Rodriguez-Canales J; Mino B; Roszik J; Tong P; Wang J; Lee JJ; Myung JH; Heymach JV; Johnson FM; Hong S; Zheng L; Hu S; Villalobos PA; Behrens C; Wistuba I; Freemantle S; Liu X; Dmitrovsky E
    J Natl Cancer Inst; 2017 Jun; 109(6):. PubMed ID: 28376145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK2 Inhibition Causes Anaphase Catastrophe in Lung Cancer through the Centrosomal Protein CP110.
    Hu S; Danilov AV; Godek K; Orr B; Tafe LJ; Rodriguez-Canales J; Behrens C; Mino B; Moran CA; Memoli VA; Mustachio LM; Galimberti F; Ravi S; DeCastro A; Lu Y; Sekula D; Andrew AS; Wistuba II; Freemantle S; Compton DA; Dmitrovsky E
    Cancer Res; 2015 May; 75(10):2029-38. PubMed ID: 25808870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK2 inhibition disorders centrosome stoichiometry and alters cellular outcomes in aneuploid cancer cells.
    Chen Z; Liu X; Kawakami M; Liu X; Baker A; Bhatawadekar A; Tyutyunyk-Massey L; Narayan K; Dmitrovsky E
    Cancer Biol Ther; 2023 Dec; 24(1):2279241. PubMed ID: 38031910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers.
    Kawakami M; Mustachio LM; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2018 Apr; 17(4):724-731. PubMed ID: 29559545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown.
    Hu S; Lu Y; Orr B; Godek K; Mustachio LM; Kawakami M; Sekula D; Compton DA; Freemantle S; Dmitrovsky E
    Mol Cancer Ther; 2015 Nov; 14(11):2576-85. PubMed ID: 26304236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TRIGGERING ANAPHASE CATASTROPHE TO COMBAT ANEUPLOID CANCERS.
    Dmitrovsky E; Kawakami M; Liu XI; Freemantle SJ; Kurie JM
    Trans Am Clin Climatol Assoc; 2020; 131():82-94. PubMed ID: 32675848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
    Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
    Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe.
    Galimberti F; Thompson SL; Liu X; Li H; Memoli V; Green SR; DiRenzo J; Greninger P; Sharma SV; Settleman J; Compton DA; Dmitrovsky E
    Clin Cancer Res; 2010 Jan; 16(1):109-20. PubMed ID: 20028770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaphase catastrophe is a target for cancer therapy.
    Galimberti F; Thompson SL; Ravi S; Compton DA; Dmitrovsky E
    Clin Cancer Res; 2011 Mar; 17(6):1218-22. PubMed ID: 21288923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy.
    Zheng L; Chen Z; Kawakami M; Chen Y; Roszik J; Mustachio LM; Kurie JM; Villalobos P; Lu W; Behrens C; Mino B; Solis LM; Silvester J; Thu KL; Cescon DW; Rodriguez-Canales J; Wistuba II; Mak TW; Liu X; Dmitrovsky E
    Mol Cancer Ther; 2019 Oct; 18(10):1775-1786. PubMed ID: 31358662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer.
    Frame S; Saladino C; MacKay C; Atrash B; Sheldrake P; McDonald E; Clarke PA; Workman P; Blake D; Zheleva D
    PLoS One; 2020; 15(7):e0234103. PubMed ID: 32645016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer.
    Somarelli JA; Roghani RS; Moghaddam AS; Thomas BC; Rupprecht G; Ware KE; Altunel E; Mantyh JB; Kim SY; McCall SJ; Shen X; Mantyh CR; Hsu DS
    Mol Cancer Ther; 2020 Dec; 19(12):2516-2527. PubMed ID: 33158998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Inhibition of CDK4 and CDK2 via Targeting p27 Tyrosine Phosphorylation Induces a Potent and Durable Response in Breast Cancer Cells.
    Patel P; Tsiperson V; Gottesman SRS; Somma J; Blain SW
    Mol Cancer Res; 2018 Mar; 16(3):361-377. PubMed ID: 29330290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 6,7,4'-trihydroxyisoflavone inhibits HCT-116 human colon cancer cell proliferation by targeting CDK1 and CDK2.
    Lee DE; Lee KW; Jung SK; Lee EJ; Hwang JA; Lim TG; Kim BY; Bode AM; Lee HJ; Dong Z
    Carcinogenesis; 2011 Apr; 32(4):629-35. PubMed ID: 21258042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of vanoxerine dihydrochloride as a CDK2/4/6 triple-inhibitor for the treatment of human hepatocellular carcinoma.
    Zhu Y; Ke KB; Xia ZK; Li HJ; Su R; Dong C; Zhou FM; Wang L; Chen R; Wu SG; Zhao H; Gu P; Leung KS; Wong MH; Lu G; Zhang JY; Jiang BH; Qiu JG; Shi XN; Lin MC
    Mol Med; 2021 Feb; 27(1):15. PubMed ID: 33579185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of CDK-mediated Smad3 phosphorylation reduces the Pin1-Smad3 interaction and aggressiveness of triple negative breast cancer cells.
    Thomas AL; Lind H; Hong A; Dokic D; Oppat K; Rosenthal E; Guo A; Thomas A; Hamden R; Jeruss JS
    Cell Cycle; 2017 Aug; 16(15):1453-1464. PubMed ID: 28678584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cdc2 and Cdk2 play critical roles in low dose doxorubicin-induced cell death through mitotic catastrophe but not in high dose doxorubicin-induced apoptosis.
    Park SS; Eom YW; Choi KS
    Biochem Biophys Res Commun; 2005 Sep; 334(4):1014-21. PubMed ID: 16036217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo.
    Cocco E; Lopez S; Black J; Bellone S; Bonazzoli E; Predolini F; Ferrari F; Schwab CL; Menderes G; Zammataro L; Buza N; Hui P; Wong S; Zhao S; Bai Y; Rimm DL; Ratner E; Litkouhi B; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Br J Cancer; 2016 Jul; 115(3):303-11. PubMed ID: 27351214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclin-dependent kinase 2 inhibitor down-regulates interleukin-1beta-mediated induction of cyclooxygenase-2 expression in human lung carcinoma cells.
    Mukhopadhyay P; Ali MA; Nandi A; Carreon P; Choy H; Saha D
    Cancer Res; 2006 Feb; 66(3):1758-66. PubMed ID: 16452236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.